Global Carrier Screening Market 2023-2030

Description

List of Tables

Title: Global Carrier Screening Market Size, Share & Trends Analysis Report by Type (Expanded Carrier Screening, and Targeted Disease Carrier Screening), by Medical Condition (Hematological, Pulmonary, Neurological, and Others), by Technology (DNA Sequencing, Polymerase Chain Reaction (PCR), Microarrays, and Others), and by End User (Hospitals and Clinics, Reference Laboratories, Government and Public Health Programs, and Others)Forecast Period (2023-2030).

The global carrier screening market is anticipated to grow at a CAGR of 17.1% during the Forecast Period (2023-2030). The market's growth is attributed to development of comprehensive testing. The availability of the FirstGene 4-in-1 prenatal screening test is part of a wider effort to improve carrier screening and prenatal care. In response to the rising need for holistic genetic insights throughout pregnancy, this comprehensive test, that covers several aspects of prenatal health and genetics, is helping to boost the global carrier screening market. For instance, in January 2023, Highlights 2023 Product Launched for Women's Health, Oncology Businesses. The Salt Lake City-based company continues to grow prepared to introduce its FirstGene 4-in-1 prenatal screening test, that covers noninvasive prenatal screening, carrier screening, fetal recessive status, and feto-maternal blood compatibility, in Q3.

Segmental Outlook

The global carrier screening market is segmented on the type, medical condition, technology, and end-user. Based on the type, the market is sub-segmented into expanded, and targeted disease. Based on the medical condition, the market is sub-segmented into hematological, pulmonary, neurological, and others. Based on the technology, the market is sub-segmented into DNA sequencing, polymerase chain reaction (PCR), microarrays, and others. Further, on the basis of end-user, the market is sub-segmented into hospitals and clinics, reference laboratories, government and public health programs, and others. The DNA sequencing subcategory is expected to capture a significant portion of the market share within the technology segment. This is attributed to the increase in humanity's vulnerability to genetic disorders. The market is also anticipated to rise as a result of increased uses for the technology in addition to increased knowledge of genetic testing instead of any ethical problems.

The Hematological Sub-Segment is Anticipated to Hold a Considerable Share of the Global Carrier Screening Market

Among the medical condition, the hematological sub-segment is expected to hold a considerable share of the global carrier screening market. The segmental growth is attributed to the growing demand for advanced diagnostic tools. The Yumizen H500 & H550 analyzers are proof of the continuously evolving diagnostic technology that reflects the growing demand for more sophisticated and effective diagnostic tools in the healthcare sector. The hematological testing process should become faster and more accurate owing to blood analyzers, that can enhance patient care. For instance, in July 2022, HORIBA Medical launched new products in its Yumizen H500 & H550 hematology product family, the portable benchtop hematology analyzers with improved functionality, new capabilities, and additional advantages. With a throughput of 60 tests per hour, 40 tubes of autonomy with continuous loading, urgent manual mode, and running samples through several analytical models and sampling, the new Yumizen H500 & H550 have been intended to offer an immediate and thorough hematological report.

Regional Outlook

The global carrier screening market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to a high prevalence of genetic disorders such as cystic fibrosis, a rise in market participants, and a significant rise in the number of tests offered in the region.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Carrier Screening Market

Among all regions, the Asia-Pacific regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the increasing demand for genetic testing and public awareness across the region. The availability of carrier screening methods and growing public awareness of genetic diseases have raised demand for genetic testing services, especially carrier screening. According to the BMC Medical Genetics, in November 2022, birth defects are abnormalities that are present from birth and can cause significant mortality, reduced productivity, and diminished quality of life. In developing countries, they have contributed to an increasing proportion of fetal, neonatal, infant and childhood mortality owing to a decline in infectious and nutritional causes such as immunizations, control of diarrheal and respiratory infections, and improved healthcare. In the West, birth defects account for 29.8% of early mortality and 29.2% of chronic problems. In India, the Sample Registration System Survey during 2010-2013 reported that congenital malformations and genetic disorders contributed 4.4, 4.6 and 4.0% to childhood mortality, infant mortality and neonatal mortality, respectively. The prevention of birth defects, including genetic disorders, is a priority in all countries, as they cause social stigmatization, economic burden, and diminish quality of life, especially in resource-poor countries.

Market Players Outlook

The major companies serving the global carrier screening market include: Congenica Ltd, Illumina, Inc., Invitae Corp., Myriad Genetics, Inc., Natera Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2022, Congenica, launched a newly developed, industry-first offering at Arab Health 2022 that combines the digital genetic profiles of both potential parents for thorough carrier screening to support family planning decisions.

The Report Covers:

Market value data analysis of 2022 and forecast to 2030.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global carrier screening market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2027829

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. DiaSorin S.p.A.
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Eurofins Scientific
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Fulgent Genetics, Inc.
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Key Strategy Analysis

4. Market Segmentation

4.1. Global Carrier Screening Market by Type
- 4.1.1. Expanded Carrier Screening
- 4.1.2. Targeted Disease Carrier Screening
4.2. Global Carrier Screening Market by Medical Condition
- 4.2.1. Hematological Conditions
- 4.2.2. Pulmonary Conditions
- 4.2.3. Neurological Conditions
- 4.2.4. Others (Familial Mediterranean Fever (FMF), and Fragile X Syndrome)
4.3. Global Carrier Screening Market by Type
- 4.3.1. DNA Sequencing
- 4.3.2. Polymerase Chain Reaction (PCR)
- 4.3.3. Microarrays
- 4.3.4. Others (Next-Generation Sequencing (NGS), Screened Conditions, and Direct-to-Consumer Testing)
4.4. Global Carrier Screening Market by End-User
- 4.4.1. Hospitals and clinics
- 4.4.2. Reference Laboratories
- 4.4.3. Government and Public Health Programs
- 4.4.4. Others (Pharmaceutical and Biotype Companies)

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Ambry Genetics Corp.
6.2. Cepheid
6.3. Congenica Ltd.
6.4. F. Hoffmann-La Roche Ltd.
6.5. Illumina, Inc.
6.6. Invitae Corp.
6.7. Laboratory Corporation of America (Labcorp)
6.8. MedGenome Inc
6.9. Myriad Genetics, Inc.
6.10. Natera Inc.
6.11. PerkinElmer AES
6.12. Quest Diagnostics Inc.
6.13. Thermo Fisher Scientific